Latest News

(UroToday.com) The field of advanced prostate cancer has rapidly progressed over the past 15 years. In the past 5 years, there has been considerable development in the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC), including chemotherapy and novel hormonal therapies (NHT). Each of these has proven survival benefits compared to the historic standard of […]

(UroToday.com) In this presentation at the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU) Dr. Peter Nelson discussed the evidence leading to the approval of the PARP inhibitors olaparib and rucaparib in advanced prostate cancer and then discussed issues surrounding biomarkers for patient selection. 

(UroToday.com) Targeting the PSMA protein is one of the most promising emerging approaches to treating advanced prostate cancer.  PSMA, the Prostate Specific Membrane Antigen, is expressed predominantly on prostate cells, as well as to a lesser degree in proximal tubules of the kidney, the small intestine, and oromaxillary glands.  As expression is further increased with prostate […]

(UroToday.com) At the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU) practical applications of novel imaging and genomic approaches in the management of clinically localized prostate cancer session, Dr. Peter Carroll discussed active surveillance for prostate cancer as it stands in 2021. Dr. Carroll notes that active surveillance is a preferred form of treatment for many […]

(UroToday.com) In 2016, Pritchard and colleagues reported that mutations in DNA-damage repair genes, particularly homologous recombination repair genes, were relatively common among patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This opened the potential for targeted therapy using poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors which lead to an accumulation of DNA single-stranded breaks which have particularly […]

(UroToday.com) The practical applications of novel imaging and genomic approaches in the management of clinically localized prostate cancer session at the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU), included a presentation by Dr. Declan Murphy who discussed the Impact of the Federal Drug Administration (FDA) approval of PSMA PET/CT in prostate cancer management. The FDA approval […]

(UroToday.com) Current guidelines for initial staging of intermediate- and high-risk prostate cancer recommend the use of cross-sectional imaging and bone scan, whereas the local staging of prostate cancer relies on systematic or targeted biopsies and multiparametric magnetic resonance imaging (mpMRI). However, the role of prostate-specific membrane antigen (PSMA)-targeted PET in the evaluation of intraprostatic cancer foci and […]

San Francisco, CA (UroToday.com) — A commercially available genomic test may help oncologists better determine which patients with recurrent prostate cancer may benefit from hormone therapy, according to new research from the Johns Hopkins Kimmel Cancer Center and 15 other medical centers.

(UroToday.com) Data from the landmark ALSYMPCA trial1 found that the targeted alpha therapy Radium-223 prolonged overall survival in men with metastatic castration-resistant prostate cancer (mCRPC).1 However, there is little data to guide clinicians as to the appropriate sequence for use of Radium-223 in men with mCRPC with regards to other life-prolonging therapies. At the 2021 ASCO Genitourinary […]

Key Points:Question: Can a genomic biomarker estimate the risk of prostate cancer clinical endpoints in men who received salvage radiation for rising prostate-specific antigen levels after surgery? Findings: In this ancillary study of 352 men randomized to placebo or hormone therapy in the NRG/RTOG 9601 clinical trial of salvage radiation, the Decipher genomic classifier was […]